Testing new treatments in cardio-metabolic disease clinical trials is a challenge that requires the right investigators at the right sites. That is what we provide.

Patient recruitment and retention in this area is notoriously difficult. Julius Clinical has the leading scientific experts, experienced local investigators, and fine-tuned screening procedures to minimize this obstacle and provide the patient enrolment and retention your trial requires.

Meet our scientific leaders for cardio-metabolic trials

Rick Grobbee
Chief Scientific Officer

Diederick E. (Rick) Grobbee is Chief Scientific Officer at Julius Clinical and a professor of clinical epidemiology at the University Medical Centre (UMC) Utrecht, the Netherlands. His other current roles include chair of the circulatory health area at UMC Utrecht.

Meet our scientific leaders for cardio-metabolic trials

We collaborate with Prof. dr. Christophe Moreno, M.D., who is an expert in gastroenterology and hepatology and clinical director of the liver unit at CUB Hôpital Erasme, Brussels, Belgium. He is a valuable consultant to our NASH Clinical team.

Highlighted trials

Our Scientific Networks

NASH Clinical

NASH Clinical is our global network of experienced clinicians and investigators with a special interest and deep experience in NASH. The network is composed of endocrinologists, gastroenterologists, diabetologists, and internists.

Read more

Cardio Clinical

Cardio Clinical is a large global network of cardiologists and researchers who focus on developing novel therapies for cardiovascular diseases. Cardio Clinical comprises 1.000+ hospitals in 32 countries, providing sites and expertise around the world. The network has been involved in various large-scale randomised intervention trials on the prevention and treatment of cardiovascular disease.

Read more

Some highligted studies

Phase III, Global


1505 Patients | 27 Countries | 485 Sites

Reducing occurrence of major cardiovascular events in high risk subjects.

Phase III, Global


560 Patients | 12 Countries | 188 Sites

Cardiovascular events in patients who are statin intolerant.

Phase III, Global


4072 Patients | 19 Countries | 436 Sites

Treatment on Cardiovascular Mortality a Morbidity in Subjects with type 2 Diabetes who experienced a recent Acute Coronary Syndrome.

Our expert cardio-metabolic team

We have an expert cardio-metabolic operational team with many years of focused experience. They are skilled at providing highly efficient, end-to-end CRO services that streamline cardio-metabolic studies and fulfil the expectations one should have for an academic CRO.

Martin czakon
Rick grobbee
Manuel castro cabezas
Marco alings
Marcel bootsma
Elizabeth liano callahan
Vivian de jong

Related webinars

  • Webinars
  • Cardio-Metabolic Diseases, NASH
  • 23-05-2023

Upcoming webinar: Why NASH trials frequently fail and how to improve them

The upcoming NASH clinical webinar promises to be an insightful and informative session, with our scientific officer Manuel Castro Cabezas as the guest speaker. Manuel will be sharing his expertise on the topic of "Why NASH trials frequently fa...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

NAFLD: patient identification strategies

In this webinar, Prof. Jörn Schattenberg discussed his paper in Nature Reviews Gastroenterology & Hepatology on effective and efficient models of care for patients with NAFLD. Standardized patient care pathways for NAFLD are not yet widely im...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

Cardio-metabolic resources

Explore our cardio-metabolic capabilities, studies, and other resources.


"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.


Twitter Facebook LinkedIn